TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05813054

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HA matrix ingredient
Description: 1 capsule/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule/day
Study: NCT06572176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: With fluorescent concretization group
Description: Nurses were given the fluorescent lotion and asked to apply it all over their hands. The CE-certified test lotion is in gel form and is safety-approved. The lotion disperses particles the same size as bacteria on the skin. These particles settle on the skin, similar to the behavior of microorganisms, but disappear with hand washing under the influence of fluorescent light. They were then asked to wash their hands with 4 ml of soap. Two researchers marked the hand washing steps independently using the Hand Washing Skill Checklist. The duration of hand washing was recorded with a mobile stopwatch for each participant. Hand washing efficiency was evaluated using the Derma Litecheck device. UV rays were used after using the test lotion and drying the hands. Since any fluorescent material left on the hands would shine under UV light, it was possible to judge how well the hands were cleansed. The dirty spots were shown to the participants, and the reason for this was discussed.
Study: NCT06160024

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Program to improve data quality of national quality indicators
Description: Interventions will be developed based on the findings from the first data collection period.~A bundle of interventions (Program to improve data quality of national quality indicators) will be offered to participating long-term care facilities to support changing behavior in data collection procedures via training and supporting material as implementation strategies with the goal to improve the data quality of the national quality indicators. The program will be tested in a separate pilot study. The second data collection period in the current study will be used to evaluate the effect of the implemented program.
Study: NCT06572540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transthoracic cryoablation
Description: Transthoracic cryoablation will be performed under the guidance of CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transbronchial cryoablation
Description: Transbronchial cryoablation will be performed under the guidance of navigation bronchoscopy and CBCT.
Study: NCT05679375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal ketamine
Description: Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous ketamine
Description: Patients will receive IV Ketamine 0.25mg/kg after spinal
Study: NCT05352139

Intervention type: PROCEDURE
Intervention: Resection (removal) of the degenerative tissue using the Hydrocision TenJet system
Description: During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.

Intervention type: PROCEDURE
Intervention: Resection (removal) of the degenerative tissue using the Hydrocision TenJet system
Description: During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.

Intervention type: PROCEDURE
Intervention: Resection (removal) of the degenerative tissue using the Hydrocision TenJet system
Description: During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.

Intervention type: DEVICE
Intervention: Hydrocision Tenjet System
Description: The TenJet system will be used during surgery to remove the damaged tissue from the joint

Intervention type: DEVICE
Intervention: Hydrocision Tenjet System
Description: The TenJet system will be used during surgery to remove the damaged tissue from the joint

Intervention type: DEVICE
Intervention: Hydrocision Tenjet System
Description: The TenJet system will be used during surgery to remove the damaged tissue from the joint
Study: NCT06155045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Carbo-dissection Technique
Description: This technique comes the C02 blower with electrocautery. Thereby, producing vasodilatation due to the gas and dissection aided by the electrocautery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Arm
Description: This technique uses only the electrocautery as conventional model
Study: NCT05855200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX
Description: CAPEOX will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: FOLFOX will be administered.
Study: NCT05886413

Intervention type: OTHER
Intervention: VentilO application
Description: This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO application, the investigators will compare the recommended settings (for mechanical ventilation) vs the real clinician settings done by clinician after patient admission in ICU after cardiac surgery. The investigators will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings.
Study: NCT06084572

Intervention type: OTHER
Intervention: Questionnaires
Description: FSSG \& BEDQ
Study: NCT05697835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication optimzation
Description: Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.

Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Description: Care as usual, with written resources provided
Study: NCT04911660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: 1 empagliflozin 25 mg capsule per day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: 1 empagliflozin 25 mg capsule per day for 14 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule per day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule per day for 14 days
Study: NCT05388201

Intervention type: OTHER
Intervention: N95
Description: 3M N95 Respirator

Intervention type: OTHER
Intervention: KN95
Description: KN95 Mask (with and without clip)

Intervention type: OTHER
Intervention: KF94
Description: KF94 Mask (with and without clip)

Intervention type: OTHER
Intervention: Surgical
Description: Surgical Mask (with and without clip)
Study: NCT06064110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictou County Person Empowerment Program
Description: The 6 month home-based program focuses on aerobic and strength training, meditation/relaxation techniques, social connection, and overall healthy lifestyle practices supported with daily email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily, the meditation/relaxation practice is 10 minutes daily, the intimacy and connection component consists of engaging in at least one form of intimacy practice prescribed, per day. Optional social connection components will be offered, such as pairing participants up with peers from the study, monthly Zoom videoconferences, and monthly in-person events in Pictou County to further promote healthy lifestyle habits.
Study: NCT05968482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Gel
Description: Topical application on both knees

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Gel
Description: Topical application on both knees

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium Gel
Description: Topical application on both knees
Study: NCT06568718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bovhyaluronidase azoximer
Description: Longidaze 3000 IU intramuscularly once every 5 days with a course of 5 injections; Longidaze 3000 IU rectal suppositories once every 3 days with a course of 10 applications; Longidaze 3000 IU rectal suppositories once every 7 days with a course of 10 applications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: Tamsulosin 0.4mg per os every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin
Description: Tamsulosin 0.4mg per os every day
Study: NCT05030922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiatherogenic diet
Description: Participants instructed in antiatherogenic diet during pregnancy with frequent follow-ups to ensure compliance
Study: NCT04496609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation and automated rehabilitation / automated rehabilitation
Description: Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated rehabilitation / Stimulation and automated rehabilitation
Description: Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
Study: NCT06526884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Next Day Clinic
Description: A dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative.
Study: NCT05728216

Intervention type: OTHER
Intervention: Dynamic full-field optical coherence tomography analysis of kidney biopsy
Description: Dynamic full-field optical coherence tomography analysis of kidney biopsy in the nephrology department before conventional histopathological analysis
Study: NCT06326112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: o.5 mg/kg bid or tid IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone Tablets
Description: Diuretic as needed
Study: NCT05089539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor-Neprilysin Inhibition
Description: Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo \[100 mg\] bid). Continuous treatment was maintained for at least three months.
Study: NCT05919394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: To compare in both treatment arms the percentage of patients controlled at week 52.
Description: Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: To compare in both treatment arms the percentage of patients controlled at week 52.
Description: Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
Study: NCT05585333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MLS laser
Description: Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
Study: NCT05063097

Intervention type: OTHER
Intervention: urine test
Description: The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol \[THC\]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.

Intervention type: OTHER
Intervention: Fagerström questionnaire
Description: Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.

Intervention type: OTHER
Intervention: Exhaled carbon monoxide (CO) measurement
Description: Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of \> 3 parts per million (ppm) signifying active smoking.
Study: NCT06486545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)
Description: Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1~DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first).
Study: NCT06040697

Intervention type: DEVICE
Intervention: Thermal Anisotropy
Description: Usability assessment observation.
Study: NCT04620434

Intervention type: DEVICE
Intervention: Video laryngoscopic view
Description: The glottic view on the screen of the video laryngoscope during laryngoscopy with a C-MAC video laryngoscope, which installed with Macintosh blade.

Intervention type: DEVICE
Intervention: Direct laryngoscopic view
Description: The glottic view evaluated by the anesthesiologist who performing tracheal intubation, by direct laryngoscopy with C-MAC installed with Macintosh blade.
Study: NCT05012592

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Awareness Program TO Reduce Malnutrition and Helminth Infestation among Primary School children
Description: This interventional study period started from September 2021 up to September 2022 (13 months) by school nurses to implement HAPSC. After completing four to five months of the educational session the school nurse will collect midline follow-up data and the endline data will be collected at the end of the interventional study. In this period a total of nine months (except annual leave) will be considered an interventional education period. The intervention group will receive one educational session per week every month. School nurses will be assigned for each class to provide health education. Each session will be conducted for a maximum of 45 minutes. The community worker will be assigned to assist the school nurse and they will communicate with the child's parents about their child's healthy nutrition and good hygiene practice. The significance of healthy eating and hygiene behavior for the children will be shared with the child's parents or guardians properly.
Study: NCT06107127

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STOP
Description: Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
Study: NCT05042622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytokine adsorber filter
Description: • Intervention group #1 a cytokine adsorber will be used (30 patients): patients on ECMO - subgroup A; septic patients - subgroup B.
Study: NCT05042622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytokine adsorber filter
Description: • Intervention group #1 a cytokine adsorber will be used (30 patients): patients on ECMO - subgroup A; septic patients - subgroup B.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal hemoperfusion cartridge
Description: • Intervention group #2 an extracorporeal hemoperfusion cartridge will be used (30 patients): patients on ECMO - subgroup C, septic patients - subgroup D.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal hemoperfusion cartridge
Description: • Intervention group #2 an extracorporeal hemoperfusion cartridge will be used (30 patients): patients on ECMO - subgroup C, septic patients - subgroup D.
Study: NCT05455567

Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA
Description: Choriocapillary vessel density calculated with OCTA

Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA
Description: Choriocapillary vessel density calculated with OCTA

Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA
Description: Choriocapillary vessel density calculated with OCTA
Study: NCT06388265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trifold information
Description: Additional detailed and written information about the procedure will be given to the participants
Study: NCT06328959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent oro-esophageal tube feeding
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gastric tube feeding
Description: In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study: NCT04727580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 10mg Q2W
Description: HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 25mg Q2W
Description: HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
Study: NCT06440668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Pain Management Workshop with Non-Pharmacological Therapies
Description: 1st Session: Welcome. Expectations. Pathophysiological mechanism of pain. Influence of emotions on pain intensity. Activities: My limiting beliefs; Affirmations in front of the mirror; Mental analgesia. / 2nd: Pain and its impact on the patient's life. Forgiveness and self-forgiveness. Ho'oponopono technique. Self-esteem. Activities: Labels that limit us; Reading When I Loved Myself for Real; Self-healing meditation; Life purpose. / 3rd: Tips to slow down aging. Promotion of healthy habits; Metta meditation; Motivation for change. / 4th: Active participation in my own healing. How to face illness. Creative visualization. Activity:Energy wheel. / 5th: Review of the tools. Resolving doubts. Workshop evaluation and scales. Guide with the tools presented. Activities: Final farewell. / At the end of each session, the homework assignments are explained, and at the beginning of the next, they are reviewed. Sessions 2, 3, 4 5: Experience of a previous workshop patient.
Study: NCT05269316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP9064
Description: IMP9064 Monotherapy administered for 21 days
Study: NCT04275232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic plasma aliquots, a source of plasminogen
Description: Plasma eye drops, a source of plasminogen
Study: NCT05577052

Intervention type: RADIATION
Group type: OTHER
Intervention: Metastatic vertebrae treated with SBRT
Description: High-dose SBRT treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Metastatic vertebrae treated with SBRT
Description: High-dose SBRT treatment
Study: NCT04984642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: have OGTT,normal diet, high fat diet, low calorie diet, and ketogenic diet in turn
Study: NCT05733429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye cervical re-education
Description: patients will receive eye-cervical re-education in the form of 10 exercises at three phases; the first phase will include stimulation of ocular mobility, the second phase will consist of Cervical mobility exercise with restricted eye movement and the third phase will include stimulation of eye and neck movement co-ordination